Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale
- PMID: 37082807
- PMCID: PMC10258159
- DOI: 10.1111/jgs.18312
Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale
Abstract
Whether initiation of statins could increase survival free of dementia and disability in adults aged ≥75 years is unknown. PREVENTABLE, a double-blind, placebo-controlled randomized pragmatic clinical trial, will compare high-intensity statin therapy (atorvastatin 40 mg) with placebo in 20,000 community-dwelling adults aged ≥75 years without cardiovascular disease, disability, or dementia at baseline. Exclusion criteria include statin use in the prior year or for >5 years and inability to take a statin. Potential participants are identified using computable phenotypes derived from the electronic health record and local referrals from the community. Participants will undergo baseline cognitive testing, with physical testing and a blinded lipid panel if feasible. Cognitive testing and disability screening will be conducted annually. Multiple data sources will be queried for cardiovascular events, dementia, and disability; survival is site-reported and supplemented by a National Death Index search. The primary outcome is survival free of new dementia or persisting disability. Co-secondary outcomes are a composite of cardiovascular death, hospitalization for unstable angina or myocardial infarction, heart failure, stroke, or coronary revascularization; and a composite of mild cognitive impairment or dementia. Ancillary studies will offer mechanistic insights into the effects of statins on key outcomes. Biorepository samples are obtained and stored for future study. These results will inform the benefit of statins for increasing survival free of dementia and disability among older adults. This is a pioneering pragmatic study testing important questions with low participant burden to align with the needs of the growing population of older adults.
Trial registration: ClinicalTrials.gov NCT04262206.
Keywords: cognition; dementia; healthy aging; older adults; statins.
© 2023 The American Geriatrics Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Conflict of interest statement
Thomas M. Gill is supported by P30AG021342 and 5UL1TR001863. Dr. Pajewski is supported by P30AG021332, R01HL155396, and R01AG071807. Dr Roumie is supported in part by CX000570-10 and the Center for Diabetes Translation Research P30DK092986.
Daniel E. Forman is supported by NIH awards R01AG060499, R01AG058883, and P30AG02482, and VHA MERIT award I01HX003518.
L. Kristin Newby reports research funding from NHLBI, NIA, NICHD, NC DHHS, BioKier, Roche Diagnostics; Consulting/advisory board for CSL-Behring, Medtronic, Beckman-Coulter, NHLBI; Non-funded “other” for BOD DHMRI, BOT AZ Healthcare Foundation.
Jacob Joseph reports research funding from NIH, Veterans Health Administration, Amgen, Kowa, and Alnylam.
Kenneth Schmader reports support from the Duke Pepper Older Americans Independence Center (NIA P30AG028716).
Michael Shapiro reports scientific advisory boards: Amgen, Novartis, NovoNordisk; Consulting: Ionis, Regeneron.
W. Schuyler Jones reports research grants from Bayer Boehringer Ingelheim, Merck, National Institutes of Health, Patient-Centered Outcomes Research Institute; Honoraria/Advisory Committees from Bayer, Bristol-Myers Squibb, Janssen Pharmaceuticals.
Catherine P. Benzinger reports site PI for studies funded by Department of Defense (WARRIOR), Amgen (VESALIUS), Novartis (INCLISIRAN), but are not relevant to the current study (does not receive financial support).
Raj C. Shah reports being the site principal investigator or sub-investigator for Alzheimer’s disease clinical trials for which his institution (Rush University Medical Center) is compensated (Amylyx Pharmaceuticals, Inc., Athira Pharma, Inc., Edgewater NEXT, Eli Lilly & Co., Inc., and Genentech, Inc.).
Christine E. Kistler reports serving as a consultant to a pharmacogenomics company, Base10, Inc. and on a pharmacogenomics advisory board for Baptist Health, FL.
Ariela R. Orkaby reports Veterans Affairs CSR&D CDA-2 award IK2-CX001800; consulting for Anthos Therapeutics.
Rowena J. Dolor reports grant funding from NIA paid to the institution for this project; PCORI, honorarium (less than $5000), as a member of the PCORI Clinical Trials Advisory Panel; Einstein-Montefiore, honorarium (less than $5000), as a member of their CTSA External Advisory Board; Veterans Administration, honorarium (less than $5000), as a consultant to the Women’s Health Practice-Based Research Network.
Karen P. Alexander reports grant funding from NIA to the institution for this project.
All other authors have nothing to report.
Figures
Similar articles
-
Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial).BMJ Open. 2023 Apr 3;13(4):e069915. doi: 10.1136/bmjopen-2022-069915. BMJ Open. 2023. PMID: 37012015 Free PMC article.
-
Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults.J Am Coll Cardiol. 2020 Jul 7;76(1):17-27. doi: 10.1016/j.jacc.2020.05.016. J Am Coll Cardiol. 2020. PMID: 32616158 Free PMC article. Clinical Trial.
-
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.JAMA Cardiol. 2017 Dec 1;2(12):1385-1391. doi: 10.1001/jamacardio.2017.3944. JAMA Cardiol. 2017. PMID: 29117276 Free PMC article. Clinical Trial.
-
Association of blood lipids, atherosclerosis and statin use with dementia and cognitive impairment after stroke: A systematic review and meta-analysis.Ageing Res Rev. 2020 Jan;57:100962. doi: 10.1016/j.arr.2019.100962. Epub 2019 Sep 7. Ageing Res Rev. 2020. PMID: 31505259
-
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2022 Aug 23;328(8):754-771. doi: 10.1001/jama.2022.12138. JAMA. 2022. PMID: 35997724
Cited by
-
Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials.Clin Trials. 2023 Oct;20(5):507-516. doi: 10.1177/17407745231177046. Epub 2023 May 26. Clin Trials. 2023. PMID: 37243355 Free PMC article.
-
Deprescribing Cardiovascular Medications in Older Adults Living with Frailty.CJC Open. 2024 Sep 25;6(12):1503-1512. doi: 10.1016/j.cjco.2024.09.008. eCollection 2024 Dec. CJC Open. 2024. PMID: 39735941 Free PMC article. Review.
-
Association of lipid-lowering therapy with dementia and cognitive outcomes: a systematic review and meta-analysis.Age Ageing. 2025 Aug 1;54(8):afaf219. doi: 10.1093/ageing/afaf219. Age Ageing. 2025. PMID: 40794911 Free PMC article.
-
Acute Myocardial Infarction and Risk of Cognitive Impairment and Dementia: A Review.Biology (Basel). 2023 Aug 21;12(8):1154. doi: 10.3390/biology12081154. Biology (Basel). 2023. PMID: 37627038 Free PMC article. Review.
-
Awaiting the verdict: Statins and the road ahead for primary prevention in older adults.J Am Geriatr Soc. 2024 Feb;72(2):332-336. doi: 10.1111/jgs.18764. Epub 2024 Jan 13. J Am Geriatr Soc. 2024. PMID: 38217414 Free PMC article. No abstract available.
References
-
- Census.gov. Available at: https://www.census.gov/content/dam/Census/library/publications/2020/demo.... Accessed October 18, 2022.
-
- Bernard MA, Clayton JA, Lauer MS. Inclusion Across the Lifespan: NIH Policy for Clinical Research. JAMA 2018;320:1535–1536. - PubMed
-
- Mangione CM, Barry MJ, Nicholson WK, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventative Services Task Force Recommendation Statement. JAMA 2022;328:746–753. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- R01 AG071807/AG/NIA NIH HHS/United States
- R01 AG058883/AG/NIA NIH HHS/United States
- P30 DK092986/DK/NIDDK NIH HHS/United States
- UL1 TR001863/TR/NCATS NIH HHS/United States
- IK2 CX001800/CX/CSRD VA/United States
- U24 TR001608/TR/NCATS NIH HHS/United States
- U19 AG065188/AG/NIA NIH HHS/United States
- R01 AG060499/AG/NIA NIH HHS/United States
- I01 CX000570/CX/CSRD VA/United States
- P30 AG021342/AG/NIA NIH HHS/United States
- P30 AG028716/AG/NIA NIH HHS/United States
- P30 AG072947/AG/NIA NIH HHS/United States
- P30 AG021332/AG/NIA NIH HHS/United States
- I01 HX003518/HX/HSRD VA/United States
- R01 HL155396/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical